McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.
Analyst recommendations
McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.
McKesson Co. (NYSE:MCK – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, Marketbeat reports. Two investment ...
Fisher Asset Management LLC lifted its stake in McKesson Co. (NYSE:MCK – Free Report) by 50.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission ...
McKesson Co. (NYSE:MCK – Free Report) – Stock analysts at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for McKesson in a research note issued to investors on Wednesday ...